1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
A disease with two faces? Re-naming ME/CFS
Persuasion Smith covers the bases on the misleading and disreputable name for our disease we've all been saddled with ...
Discuss the article on the Forums.

Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected

Discussion in 'Antivirals, Antibiotics and Immune Modulators' started by Ema, Apr 3, 2014.

  1. Ema

    Ema Senior Member

    Messages:
    3,492
    Likes:
    3,968
    Midwest USA
    I have the whole paper if anyone is interested...



    J Clin Virol. 2006 Dec;37 Suppl 1:S69-75.
    Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts.
    Naesens L1, Bonnafous P, Agut H, De Clercq E.
    Author information

    Abstract
    BACKGROUND:
    HHV-6 replication requires complex and poorly understood interactions between viral and cellular factors.

    OBJECTIVES:
    Several natural compounds or broad-acting pharmacological agents were studied in an attempt to discover new targets for anti-HHV-6 therapy.

    STUDY DESIGN:
    The antiviral activity was determined in human T-lymphoblasts, using HHV-6A (GS)-infected HSB-2 cells, HHV-6B (Z29)-infected MOLT-3 cells and HHV- 6B (HST)-infected MT4 cells. Virus replication was measured by CPE and qPCR assay. Foscarnet was included as the reference compound.

    RESULTS:
    Among the 15 natural compounds tested, only 'red marine algae' (an extract rich in sulfated polysaccharides) exhibited strong activity when added during virus adsorption. Among the broad-acting pharmacological agents, chloroquine, artemisinin, hypericin, ribavirin, resveratrol and glycyrrhizic acid were all inactive. Amantadine produced a reproducible inhibition of HHV-6 replication, albeit at relatively high concentrations. Except for lamotrigine, which was moderately active against HHV-6B, several antiepileptic drugs were shown to have no activity. We included several compounds which we previously described as potent HHV-6 inhibitors, i.e., the non-nucleoside inhibitor CMV423 and the acyclic nucleoside phosphonate analogues cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-3-deazaadenine. The latter compound exhibited remarkable anti-HHV-6 activity.

    CONCLUSION:
    Further optimization of compounds belonging to diverse classes of antiherpetic agents, for their specific action against HHV-6, is warranted.
     
    Iquitos, heapsreal and SOC like this.

See more popular forum discussions.

Share This Page